Drug Profile
AVI 7288
Alternative Names: AVI-7288Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator AVI BioPharma
- Developer Sarepta Therapeutics; United States Department of Defense
- Class Antisense oligonucleotides; Antivirals
- Mechanism of Action RNA interference; Viral RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Marburg virus disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Marburg virus disease(In volunteers) in USA (IV, Infusion)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Marburg virus disease in USA (IM)
- 10 Feb 2014 Adverse events data from a phase I, multiple ascending dose (MAD) trial in Marburg virus disease (in volunteers) released by Sarepta Therapeutics